Joseph I Clark, MD
Medical Oncology, Hematology & Oncology, Internal Medicine
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Primary Contact
(888)584-7888
Services & Specialties
Areas of Specialization
- Hematology & Oncology
- Internal Medicine
- Medical Oncology
Locations & Contact
Primary Location
Loyola University Medical Center
2160 S First Ave
Maywood
, IL 60153
View hours
Tuesday
8:00am
- 5:00pm
Monday
8:00am
- 5:00pm
Wednesday
8:00am
- 5:00pm
Thursday
8:00am
- 5:00pm
Friday
8:00am
- 5:00pm
Saturday
8:00am
- 5:00pm
Sunday
8:00am
- 5:00pm
Edward Hines Jr Veterans Administration Hospital
5000 S 5th Ave
5000 S 5th Ave
Hines
, IL 60141
About
I am a medical oncologist here at Loyola with a particular clinical and research interest in the treatment of patients with malignant melanoma, and other skin cancers, kidney cancer, head and neck cancer, salivary gland cancers, and thyroid cancers. I work closely with our surgical oncology and our radiation oncology colleagues to offer the best possible treatment options available to each individual patient. I take a caring approach to all those I treat as if they were my own family member.
Academic Title
Professor
Leadership Title
Regional Director - Oncology Service Line
Division Director, Hematology - Oncology
Ages Seen
Adults - Over 65
Adults - 18 to 64
Procedures Performed
- cancer
Additional Resources
Education & Certifications
Education
Education:
University of Illinois at Urbana-Champaign
(1984)
Education:
Loyola University Stritch School of Medicine
(1989)
Residency:
Loyola University Medical Center
(1992)
Fellowship:
Fox Chase Cancer Center
(1995)
Board Certifications
Medical Oncology, Medical Oncology, American Board of Internal Medicine Subspecialty (1995)
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Publications
- Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. Lara, P. N.; Tangen, C.; Heath, E. I.; Gulati, S.; Stein, M. N.; Meng, M.; Alva, A. S.; Pal, S. K.; Puzanov, I.; Clark, J. I.; Choueiri, T. K.; Agarwal, N.; Uzzo, R.; Haas, N. B.; Synold, T. W.; Plets, M.; Vaishampayan, U. N.; Shuch, B. M.; Lerner, S.; Thompson, I. M.; Ryan, C. W.; European urology
- Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Ryan, C. W.; Tangen, C. M.; Heath, E. I.; Stein, M. N.; Meng, M. V.; Alva, A. S.; Pal, S. K.; Puzanov, I.; Clark, J. I.; Choueiri, T. K.; Agarwal, N.; Uzzo, R. G.; Haas, N. B.; Synold, T. W.; Plets, M.; Vaishampayan, U. N.; Shuch, B. M.; Thompson, I. M.; Lara, P. N.; Lancet (London, England)
- Implementing a cognitive behavioral intervention for patients with head and neck cancer. Thilges, S.; Mumby, P.; Sinacore, J.; Clark, J.; Czerlanis, C.; Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
- Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. Abou Elkassem, A. M.; Lo, S. S.; Gunn, A. J.; Shuch, B. M.; Dewitt-Foy, M. E.; Abouassaly, R.; Vaidya, S. S.; Clark, J. I.; Louie, A. V.; Siva, S.; Grosu, A. L.; Smith, A. D.; Radiographics : a review publication of the Radiological Society of North America, Inc
- HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells. Moore, T. V.; Scurti, G. M.; DeJong, M.; Wang, S. Y.; Dalheim, A. V.; Wagner, C. R.; Hutchens, K. A.; Speiser, J. J.; Godellas, C. V.; Fountain, C.; Fleser, J.; Moudgil, T.; Thomas, M.; Murray, D.; Curti, B. D.; Clark, J. I.; Fox, B. A.; Nishimura, M. I.; Molecular therapy oncolytics
- Cytoreductive Nephrectomy for Synchronous Metastatic Renal Cell Carcinoma-Are There Any Favorable Risk Patients? Patel, H. D.; Clark, J. I.; Flanigan, R. C.; The Journal of urology
- Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2. Clark, J. I.; Curti, B.; Davis, E. J.; Kaufman, H.; Amin, A.; Alva, A.; Logan, T. F.; Hauke, R.; Miletello, G. P.; Vaishampayan, U.; Johnson, D. B.; White, R. L.; Wiernik, P. H.; Dutcher, J. P.; Journal of investigative medicine : the official publication of the American Federation for Clinical Research
- Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Algazi, A. P.; Othus, M.; Daud, A. I.; Lo, R. S.; Mehnert, J. M.; Truong, T. G.; Conry, R.; Kendra, K.; Doolittle, G. C.; Clark, J. I.; Messino, M. J.; Moore, D. F.; Lao, C.; Faller, B. A.; Govindarajan, R.; Harker-Murray, A.; Dreisbach, L.; Moon, J.; Grossmann, K. F.; Ribas, A.; Nature medicine
- High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Silk, A. W.; Kaufman, H. L.; Curti, B.; Mehnert, J. M.; Margolin, K.; McDermott, D.; Clark, J.; Newman, J.; Bommareddy, P. K.; Denzin, L.; Najmi, S.; Haider, A.; Shih, W.; Kane, M. P.; Zloza, A.; Frontiers in oncology
- Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma. Principe, D. R.; Clark, J. I.; Emami, B.; Borowicz, S.; BMJ case reports
- Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. Fishman, M.; Dutcher, J. P.; Clark, J. I.; Alva, A.; Miletello, G. P.; Curti, B.; Agarwal, N.; Hauke, R.; Mahoney, K. M.; Moon, H.; Treisman, J.; Tykodi, S. S.; Daniels, G.; Morse, M. A.; Wong, M. K. K.; Kaufman, H.; Gregory, N.; McDermott, D. F.; Journal for immunotherapy of cancer
- Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. Buchbinder, E. I.; Dutcher, J. P.; Daniels, G. A.; Curti, B. D.; Patel, S. P.; Holtan, S. G.; Miletello, G. P.; Fishman, M. N.; Gonzalez, R.; Clark, J. I.; Richart, J. M.; Lao, C. D.; Tykodi, S. S.; Silk, A. W.; McDermott, D. F.; Journal for immunotherapy of cancer
- Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Bajic, P.; Flanigan, R. C.; Joyce, C. J.; Clark, J. I.; The Journal of urology
- A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. Clark, J. I.; Singh, J.; Ernstoff, M. S.; Lao, C. D.; Flaherty, L. E.; Logan, T. F.; Curti, B.; Agarwala, S. S.; Taback, B.; Cranmer, L.; Lutzky, J.; Luna, T. L.; Aung, S.; Lawson, D. H.; Journal for immunotherapy of cancer
- Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report. Clark, J. I.; Bufalino, S.; Singh, S.; Borys, E.; Journal for immunotherapy of cancer
- An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. Sullivan, R. J.; Atkins, M. B.; Kirkwood, J. M.; Agarwala, S. S.; Clark, J. I.; Ernstoff, M. S.; Fecher, L.; Gajewski, T. F.; Gastman, B.; Lawson, D. H.; Lutzky, J.; McDermott, D. F.; Margolin, K. A.; Mehnert, J. M.; Pavlick, A. C.; Richards, J. M.; Rubin, K. M.; Sharfman, W.; Silverstein, S.; Slingluff, C. L.; Sondak, V. K.; Tarhini, A. A.; Thompson, J. A.; Urba, W. J.; White, R. L.; Whitman, E. D.; Hodi, F. S.; Kaufman, H. L.; Journal for immunotherapy of cancer
- Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Moore, T.; Wagner, C. R.; Scurti, G. M.; Hutchens, K. A.; Godellas, C.; Clark, A. L.; Kolawole, E. M.; Hellman, L. M.; Singh, N. K.; Huyke, F. A.; Wang, S. Y.; Calabrese, K. M.; Embree, H. D.; Orentas, R.; Shirai, K.; Dellacecca, E.; Garrett-Mayer, E.; Li, M.; Eby, J. M.; Stiff, P. J.; Evavold, B. D.; Baker, B. M.; Le Poole, I. C.; Dropulic, B.; Clark, J. I.; Nishimura, M. I.; Cancer immunology, immunotherapy : CII
- Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. Curti, B.; Daniels, G. A.; McDermott, D. F.; Clark, J. I.; Kaufman, H. L.; Logan, T. F.; Singh, J.; Kaur, M.; Luna, T. L.; Gregory, N.; Morse, M. A.; Wong, M. K. K.; Dutcher, J. P.; Journal for immunotherapy of cancer
- Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. Moore, T.; Wagner, C. R.; Scurti, G. M.; Hutchens, K. A.; Godellas, C.; Clark, A. L.; Kolawole, E. M.; Hellman, L. M.; Singh, N. K.; Huyke, F. A.; Wang, S. Y.; Calabrese, K. M.; Embree, H. D.; Orentas, R.; Shirai, K.; Dellacecca, E.; Garrett-Mayer, E.; Li, M.; Eby, J. M.; Stiff, P. J.; Evavold, B. D.; Baker, B. M.; Le Poole, I. C.; Dropulic, B.; Clark, J. I.; Nishimura, M. I.; Cancer immunology, immunotherapy : CII
- Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Atkins, M. B.; Clark, J. I.; Quinn, D. I.; Annals of oncology : official journal of the European Society for Medical Oncology
- Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. Clark, J. I.; Wong, M. K. K.; Kaufman, H. L.; Daniels, G. A.; Morse, M. A.; McDermott, D. F.; Agarwala, S. S.; Lewis, L. D.; Stewart, J. H.; Vaishampayan, U.; Curti, B.; Gonzalez, R.; Lutzky, J.; Rudraptna, V.; Cranmer, L. D.; Jeter, J. M.; Hauke, R. J.; Miletello, G.; Milhem, M. M.; Amin, A.; Richart, J. M.; Fishman, M.; Hallmeyer, S.; Patel, S. P.; Van Veldhuizen, P.; Agarwal, N.; Taback, B.; Treisman, J. S.; Ernstoff, M. S.; Perritt, J. C.; Hua, H.; Rao, T. B.; Dutcher, J. P.; Aung, S.; Clinical genitourinary cancer
- Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma. Klarquist, J.; Tobin, K.; Farhangi Oskuei, P.; Henning, S. W.; Fernandez, M. F.; Dellacecca, E. R.; Navarro, F. C.; Eby, J. M.; Chatterjee, S.; Mehrotra, S.; Clark, J. I.; Le Poole, I. C.; Cancer research
- Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Alva, A.; Daniels, G. A.; Wong, M. K.; Kaufman, H. L.; Morse, M. A.; McDermott, D. F.; Clark, J. I.; Agarwala, S. S.; Miletello, G.; Logan, T. F.; Hauke, R. J.; Curti, B.; Kirkwood, J. M.; Gonzalez, R.; Amin, A.; Fishman, M.; Agarwal, N.; Lowder, J. N.; Hua, H.; Aung, S.; Dutcher, J. P.; Cancer immunology, immunotherapy : CII
- A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. Buchbinder, E. I.; Gunturi, A.; Perritt, J.; Dutcher, J.; Aung, S.; Kaufman, H. L.; Ernstoff, M. S.; Miletello, G. P.; Curti, B. D.; Daniels, G. A.; Patel, S. P.; Kirkwood, J. M.; Hallmeyer, S.; Clark, J. I.; Gonzalez, R.; Richart, J. M.; Lutzky, J.; Morse, M. A.; Sullivan, R. J.; McDermott, D. F.; Journal for immunotherapy of cancer
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. Johnson, D. B.; Sullivan, R. J.; Ott, P. A.; Carlino, M. S.; Khushalani, N. I.; Ye, F.; Guminski, A.; Puzanov, I.; Lawrence, D. P.; Buchbinder, E. I.; Mudigonda, T.; Spencer, K.; Bender, C.; Lee, J.; Kaufman, H. L.; Menzies, A. M.; Hassel, J. C.; Mehnert, J. M.; Sosman, J. A.; Long, G. V.; Clark, J. I.; JAMA oncology
- Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face. Block, A. M.; Alite, F.; Diaz, A. Z.; Borrowdale, R. W.; Clark, J. I.; Choi, M.; Case reports in oncological medicine
- Robust Differences in p16-Dependent Oropharyngeal Squamous Cell Carcinoma Distant Metastasis: Implications for Targeted Therapy. Jaber, J. J.; Murrill, L.; Clark, J. I.; Johnson, J. T.; Feustel, P. J.; Mehta, V.; Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
- Multidisciplinary treatment of olfactory neuroblastoma: Patterns of failure and management of recurrence. Petruzzelli, G. J.; Howell, J. B.; Pederson, A.; Origitano, T. C.; Byrne, R. W.; Munoz, L.; Emami, B.; Clark, J. I.; American journal of otolaryngology
- Ipilimumab for the treatment of melanoma. Jain, S.; Clark, J. I.; Melanoma management
- The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. McDermott, D. F.; Cheng, S. C.; Signoretti, S.; Margolin, K. A.; Clark, J. I.; Sosman, J. A.; Dutcher, J. P.; Logan, T. F.; Curti, B. D.; Ernstoff, M. S.; Appleman, L.; Wong, M. K.; Khushalani, N. I.; Oleksowicz, L.; Vaishampayan, U. N.; Mier, J. W.; Panka, D. J.; Bhatt, R. S.; Bailey, A. S.; Leibovich, B. C.; Kwon, E. D.; Kabbinavar, F. F.; Belldegrun, A. S.; Figlin, R. A.; Pantuck, A. J.; Regan, M. M.; Atkins, M. B.; Clinical cancer research : an official journal of the American Association for Cancer Research
- Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Escudier, B.; Michaelson, M. D.; Motzer, R. J.; Hutson, T. E.; Clark, J. I.; Lim, H. Y.; Porfiri, E.; Zalewski, P.; Kannourakis, G.; Staehler, M.; Tarazi, J.; Rosbrook, B.; Cisar, L.; Hariharan, S.; Kim, S.; Rini, B. I.; British journal of cancer
- A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. Dandamudi, U. B.; Ghebremichael, M.; Sosman, J. A.; Clark, J. I.; McDermott, D. F.; Atkins, M. B.; Dutcher, J. P.; Urba, W. J.; Regan, M. M.; Puzanov, I.; Crocenzi, T. S.; Curti, B. D.; Vaishampayan, U. N.; Crosby, N. A.; Margolin, K. A.; Ernstoff, M. S.; Journal of immunotherapy (Hagerstown, Md. : 1997)
- Evolving treatment strategies in thin cutaneous head and neck melanoma: 1 institution's experience. Jaber, J. J.; Clark, J. I.; Muzaffar, K.; Ruggiero, F. P.; Feustel, P. J.; Frett, M. J.; Zender, C. A.; Head & neck
- Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Clark, J. I.; Moon, J.; Hutchins, L. F.; Sosman, J. A.; Kast, W. M.; Da Silva, D. M.; Liu, P. Y.; Thompson, J. A.; Flaherty, L. E.; Sondak, V. K.; Cancer
- Phase I adjuvant radiation with docetaxel in high-risk head and neck cancer. Clark, J. I.; Eisner, R. M.; Hofmeister, C.; Norton, J.; Thomas, S.; Choudhury, A.; Petruzzelli, G.; Lathers, D.; Young, M. R.; Lau, A.; Emami, B.; American journal of clinical oncology
- Clinicopathological review: esthesioneuroblastoma. Bragg, T. M.; Scianna, J.; Kassam, A.; Emami, B.; Brown, H. G.; Hacein-Bey, L.; Clark, J. I.; Muzaffar, K.; Boulis, N.; Prabhu, V. C.; Neurosurgery
- Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study. Clark, J. I.; Mehrabi, J.; Sosman, J. A.; Logan, T. F.; Margolin, K. A.; Dutcher, J. P.; Urba, W. J.; Ernstoff, M. S.; McDermott, D. F.; Lau, A. M.; Atkins, M. B.; Journal of immunotherapy (Hagerstown, Md. : 1997)
- Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Meyer, P. N.; Clark, J. I.; Flanigan, R. C.; Picken, M. M.; American journal of clinical pathology
- Passive seeding in metanephric adenoma: a review of pseudometastatic lesions in perinephric lymph nodes. Paner, G. P.; Turk, T. M.; Clark, J. I.; Lindgren, V.; Picken, M. M.; Archives of pathology & laboratory medicine
- Review. Farray, D.; Clark, J. I.; Clinical advances in hematology & oncology : H&O
- Neoadjuvant therapy: an emerging concept in oncology. Tanvetyanon, T.; Clark, J. I.; Campbell, S. C.; Lo, S. S.; Southern medical journal
- Case report and brief review: IL-2-induced myocarditis. Eisner, R. M.; Husain, A.; Clark, J. I.; Cancer investigation
- Metastatic juxtaglomerular cell tumor in a 52-year-old man. Duan, X.; Bruneval, P.; Hammadeh, R.; Fresco, R.; Eble, J. N.; Clark, J. I.; Vigneswaran, W. T.; Flanigan, R. C.; Picken, M. M.; The American journal of surgical pathology
- Posterior marginal mandibulectomy in the management of cancer of the oral cavity and oropharynx. Petruzzelli, G. J.; Knight, F. K.; Vandevender, D.; Clark, J. I.; Emami, B.; Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
- Metastatic renal cell carcinoma. Flanigan, R. C.; Campbell, S. C.; Clark, J. I.; Picken, M. M.; Current treatment options in oncology
- Nephrectomy in metastatic renal cell carcinoma. Campbell, S. C.; Flanigan, R. C.; Clark, J. I.; Current treatment options in oncology
- Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. Clark, J. I.; Atkins, M. B.; Urba, W. J.; Creech, S.; Figlin, R. A.; Dutcher, J. P.; Flaherty, L.; Sosman, J. A.; Logan, T. F.; White, R.; Weiss, G. R.; Redman, B. G.; Tretter, C. P.; McDermott, D.; Smith, J. W.; Gordon, M. S.; Margolin, K. A.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Naeem, M.; Dahiya, M.; Clark, J. I.; Creech, S. D.; Alkan, S.; Human pathology
- Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. Albain, K. S.; Crowley, J. J.; Turrisi, A. T.; Gandara, D. R.; Farrar, W. B.; Clark, J. I.; Beasley, K. R.; Livingston, R. B.; Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report. Ruzich, J. C.; Ciesla, M. C.; Clark, J. I.; Head & neck
- Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Clark, J. I.; Hofmeister, C.; Choudhury, A.; Matz, G.; Collins, S.; Bastian, R.; Melian, E.; Emami, B.; Petruzzelli, G.; Cancer
- Metanephric adenosarcoma in a young adult: morphologic, immunophenotypic, ultrastructural, and fluorescence in situ hybridization analyses: a case report and review of the literature. Picken, M. M.; Curry, J. L.; Lindgren, V.; Clark, J. I.; Eble, J. N.; The American journal of surgical pathology
- Combined modality therapy for early stage operable and locally advanced potentially resectable non-small cell lung carcinoma. Clark, J. I.; Albain, K. S.; Cancer treatment and research
- Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Nikitina, E. Y.; Clark, J. I.; Van Beynen, J.; Chada, S.; Virmani, A. K.; Carbone, D. P.; Gabrilovich, D. I.; Clinical cancer research : an official journal of the American Association for Cancer Research
- Role of cytokines in pathology of melanoma and use of biologic response modifiers in melanoma. Clark, J. I.; Methods in molecular medicine
- New therapeutic strategies for the treatment and prevention of head and neck cancer. Lingen, M. W.; Emami, B.; Clark, J. I.; Expert opinion on investigational drugs